The active ingredient, tirzepatide, isn't what's new here. It was patented in 2016 and has been on the market for treating type 2 diabetes since 2021.
What's new is that tirzepatide is now FDA approved for treatment of obesity, which will make it possible for insurance to cover it without a type 2 diabetes diagnosis.
It should also be noted that during those original studies significant weight loss was observed, which is why doctor's were prescribing tirzepatide off-label.
Also just like Ozempic/Wegovy, Mounjaro is still indicated for type 2 diabetes. Zepbound will be the weight loss drug.
https://www.nejm.org/doi/full/10.1056/nejmoa2107519
I think retatrutide might be the current leader for weight loss from clinical trials.
If I remember correctly, you lost the same amount of weight on retatrutide vs tirzepatide, but over a shorter time span.